Comparison of Bupivacaine and Exparel for Carpal Tunnel Release
- Conditions
- Pain After Carpal Tunnel Release
- Interventions
- Registration Number
- NCT02141178
- Lead Sponsor
- University of Pittsburgh
- Brief Summary
Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase.
The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Patients with carpal tunnel syndrome undergoing surgery
- Non english speaking
- Allergy to bupivacaine or exparel
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Exparel Exparel Patients will received Exparel subcutaneously for local anesthesia during surgery Bupivacaine Bupivacaine Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
- Primary Outcome Measures
Name Time Method Pain Starting immediately after surgery and then every 8 hours for 10 days Pain will be evaluated using an 11-point ordinal scale (0-10)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States